EP Patent

EP2711009A1 — Compounds for use in treating or preventing primary and metastatic breast and prostate cancer

Assigned to Institut Universitari de Ciencia i Tecnologia · Expires 2014-03-26 · 12y expired

What this patent protects

The present invention relates to the field of biotechnology. The present invention relates to a compound of formula (I) for use in the treatment or prevention of primary and metastatic breast and prostate cancer. The present invention also relates to a combination of a compound o…

USPTO Abstract

The present invention relates to the field of biotechnology. The present invention relates to a compound of formula (I) for use in the treatment or prevention of primary and metastatic breast and prostate cancer. The present invention also relates to a combination of a compound of formula (I) with at least one further compound for use in the treatment or prevention of primary and metastatic breast and prostate cancer. The present invention further relates to a pharmaceutical composition comprising the compound of formula (I) or the combination.

Drugs covered by this patent

Patent Metadata

Patent number
EP2711009A1
Jurisdiction
EP
Classification
Expires
2014-03-26
Drug substance claim
No
Drug product claim
No
Assignee
Institut Universitari de Ciencia i Tecnologia
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.